United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $16 | $10 | $13 | $10 |
| - Cash | $2 | $1 | $1 | $1 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $15 | $10 | $12 | $10 |
| Revenue | $3 | $2 | $2 | $2 |
| % Growth | 23.6% | 20.2% | 14.9% | – |
| Gross Profit | $3 | $2 | $2 | $2 |
| % Margin | 89.2% | 88.9% | 92.4% | 92.7% |
| EBITDA | $2 | $1 | $1 | $1 |
| % Margin | 57.5% | 59.6% | 53.7% | 43.7% |
| Net Income | $1 | $1 | $1 | $0 |
| % Margin | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS Diluted | 24.64 | 19.81 | 15 | 10.06 |
| % Growth | 24.4% | 32.1% | 49.1% | – |
| Operating Cash Flow | $1 | $1 | $1 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $1 | $1 | $1 | $0 |